Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy

Romesh Khardori, MD, PhD; Anne L. Peters, MD

Disclosures

May 16, 2022

Both DPP-4 inhibitors and GLP-1 RAs are effective at lowering hemoglobin A1c levels. Incretin-based therapies have a low incidence of hypoglycemia and are safe to use in patients with chronic kidney disease. In addition, studies have suggested that DDP-4 inhibitors may reduce albuminuria and improve various renal inflammatory markers. However, GLP-1 RAs and sodium-glucose cotransporter 2 (SGLT2) inhibitors more effectively lower glycemia compared with DPP-4 inhibitors.

GLP-1 RAs have been shown to lower all-cause mortality and nonfatal cardiovascular complications. Although DDP-4 inhibitors may be safe to use in patients with heart failure, they are not effective in reducing cardiovascular outcomes.

Learn more about type 2 diabetes.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....